CDKN2A and neoplasm: As virtually all human tumor cells carry aberrations throughout the cyclin–CDK4/6–RB–p16 axis to support their hyperproliferative state, selective CDK4/6 inhibitors (CDK4/6i) have been developed in recent years (Klein et al, 2018).